Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 16/20 | 0.79 |
| ▸ | JAK2 | O60674 | 1/20 | 0.54 |
| ▸ | JAK3 | P52333 | 1/20 | 0.54 |
| ▸ | IGF1R | P08069 | 1/20 | 0.48 |
| ▸ | PAK3 | O75914 | 1/20 | 0.48 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.48 |
| ▸ | PAK2 | Q13177 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4900453 | 1.00 | NTRK1 (0.79) | NTRK1JAK2JAK3IGF1RPAK3 | |
| SCHEMBL4073788 | 0.89 | NTRK1 (1.00) | NTRK1JAK2JAK3IGF1R | |
| SCHEMBL4144577 | 0.86 | NTRK1 (1.00) | NTRK1JAK2JAK3IGF1R | |
| SCHEMBL4780657 | 0.86 | NTRK1 (0.78) | NTRK1JAK2JAK3 | |
| SCHEMBL4075967 | 0.86 | NTRK1 (0.78) | NTRK1JAK2JAK3 | |
| SCHEMBL4165529 | 0.84 | NTRK1 (0.77) | NTRK1JAK2JAK3IGF1RPAK3 | |
| SCHEMBL22535576 | 0.81 | NTRK1 (0.68) | NTRK1JAK2JAK3IGF1R | |
| SCHEMBL4156718 | 0.80 | NTRK1 (0.64) | NTRK1JAK2JAK3IGF1R | |
| SCHEMBL22535694 | 0.80 | NTRK1 (0.70) | NTRK1JAK2JAK3IGF1R | |
| SCHEMBL22535847 | 0.80 | NTRK1 (0.70) | NTRK1JAK2JAK3IGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1686999-B1 | PYRAZOLE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES | ASTRAZENECA AB (SE) | 2009-07-01 | — | — | EP | disclosed |
| US-20090005396-A1 | Use of Pyrazolyl-Pyrimidine Derivatives in the Treatment of Pain | ASTRAZENECA AB (SE) | 2009-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005396-A1 | Use of Pyrazolyl-Pyrimidine Derivatives in the Treatment of Pain | P2RX3, DPYD, TYMP | NTRK1 3656/4885JAK2 1971/4885JAK3 1598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.